FTC approves Valeant asset sales for Sanofi and Johnson & Johnson deals

Feb 22, 2012

With a 4-0 vote, the FTC has approved final consent orders remedying the anticompetitive effects of Valeant Pharmaceuticals' proposed acquisitions of Sanofi and Johnson & Johnson's dermatalogy businesses. For the Sanofi deal, Valeant has sold to Mylan Pharmaceuticals the manufacturing and marketing rights to products treating acne and actinic keratosis. For the Johnson & Johnson deal, Valeant has sold to Spear Pharmaceuticals the rights to an anti-wrinkle pharmaceutical product.

The orders settle charges of Section 7 Clayton Act and Section 5 FTC Act violations.

Source: FTC Press Release

 

Related content: Consumer Protection Economics at the FTC

Links to Full Content

Comments

You can't post comments until you have logged in. Please login here or register.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments